Stephen Bardin's departure as Chief Financial Officer of CalciMedica, Inc. was reported; the filing names no successor. As of November 6, 2026, CalciMedica, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from July 7, 2026 to October 16, 2026, naming 1 appointment and 2 departures (Form 8-K, October 16, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like CalciMedica, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
CalciMedica, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-07-07 to 2026-10-16. They name 3 people, with 1 appointment and 2 departures. Every row below is cited to the filing it comes from, and this page adds each new change as CalciMedica, Inc. files it.
Also on the record for CalciMedica, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 25, 2026 | Stake report, Schedule 13G, by Stonepine Capital Management, LLC | 6% of the class | 5%+ stakes | Source |
| August 24, 2026 | Stake report, Schedule 13D/A, by Alafi Capital Company LLC | 19.9% of the class | 5%+ stakes | Source |
| August 21, 2026 | Stake report, Schedule 13D/A, by Bering Partners II GP, L.L.C. | 9.99% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G, by Armistice Capital, LLC | 9.99% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G, by Woodline Partners LP | 8.1% of the class | 5%+ stakes | Source |
| July 20, 2026 | Stake report, Schedule 13G, by CVI Investments, Inc. | 5.1% of the class | 5%+ stakes | Source |
| July 10, 2026 | Stake report, Schedule 13D, by Alafi Capital Company LLC | 17.1% of the class | 5%+ stakes | Source |
| July 2, 2026 | Stake report, Schedule 13D, by Bering Partners II GP, L.L.C. | 6.9% of the class | 5%+ stakes | Source |
| June 30, 2026 | Stake report, Schedule 13D/A, by Valence Investments SPV VI, LLC | 6.4% of the class | 5%+ stakes | Source |
| June 25, 2026 | Stake report, Schedule 13G/A, by Avenue Venture Opportunities Fund II, L.P. | 4.99% of the class | 5%+ stakes | Source |
| May 20, 2026 | Stake report, Schedule 13G/A, by Chernett Jorey | — | 5%+ stakes | Source |
| May 8, 2026 | Stake report, Schedule 13G/A, by Soleus Capital Management, L.P. | 2.4% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs CalciMedica, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on CalciMedica, Inc. and the records around it.
CalciMedica, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- Soleus Private Equity Fund III, L.P. also filed stake reports on 5 other companies: Prelude Therapeutics Inc (Jul 2026), Aprea Therapeutics, Inc. (Apr 2026), INVIVYD, INC. (Feb 2026)
- Chernett Jorey also filed stake reports on 16 other companies: CVRx, Inc. (Oct 2026), WW INTERNATIONAL, INC. (Aug 2026), Neuronetics, Inc. (Aug 2026)
- Stonepine Capital Management, LLC also filed stake reports on 17 other companies: Femasys Inc (Aug 2026), Edesa Biotech, Inc. (Aug 2026), AEON Biopharma, Inc. (Jul 2026)
Watch CalciMedica, Inc.
Get an email when CalciMedica, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on CalciMedica, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on CalciMedica, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on CalciMedica, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 19 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-16 | Out | Chief Financial Officer | 8-K, 2026-10-16 | ||
| 2026-07-07 | In | Director | 8-K, 2026-07-07 | ||
| 2026-07-07 | Out | 8-K, 2026-07-07 |
Who leads CalciMedica, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: Stephen Bardin, departure reported (filed 2026-10-16). No successor is named in these filings.
- Director: Evgeny Zaytsev, appointed (filed 2026-07-07).
New leaders reset buying decisions — get the Full Report on CalciMedica, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at CalciMedica, Inc., with the record behind each one.
Find candidates like Chief Financial Officer at CalciMedica, Inc.Every change, in the filing's words
Departing: Stephen Bardin, Chief Financial Officer
On October 15, 2026, Stephen Bardin, the Chief Financial Officer, principal accounting officer and principal financial officer of CalciMedica, Inc. (the "Company"), provided notice of his resignation, to be effective immediately following the filing of the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, to pursue another professional opportunity.
- Mr. Bardin's resignation was not due to any disagreement with the Company.
Appointed: Evgeny Zaytsev, Director
The Board, upon recommendation of the Nominating Committee, appointed Evgeny Zaytsev, M.D., Ph.D., as a Class I director of the Company, effective immediately, with a term of office expiring at the 2027 annual meeting of stockholders.
Departing: Fred Middleton
On July 2, 2026, Fred Middleton informed the Board of his intention to retire from the Board effective on the Company's 2026 annual meeting of the stockholders.
- On July 2, 2026, the board of directors (the "Board") of CalciMedica, Inc., a Delaware corporation (the "Company"), upon recommendation of the Nominating and Corporate Governance Committee of the Board (the "Nominating Committee"), increased the size of the Board from seven directors to eight directors.
- On Mr. Middleton's retirement, the size of the Board will be decreased to seven directors.
- Mr. Middleton's retirement is not the result of any disagreement with the Company on any matter relating to its operations, policies, practices or otherwise.
Tools for this story
Each opens in a new tab, filled in for CalciMedica, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.